OSE Immunotherapeutics SA (EPA:OSE)
France flag France · Delayed Price · Currency is EUR
3.176
-0.030 (-0.94%)
Aug 3, 2026, 5:22 PM CET

OSE Immunotherapeutics Balance Sheet

Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Equivalents
17.5516.7518.6725.6233.58
Short-Term Investments
14.1249.0510.82-9.85
Cash & Short-Term Investments
31.6865.7929.525.6243.43
Cash Growth
-51.86%123.06%15.13%-41.01%12.06%
Accounts Receivable
0.314.140.980.4-
Other Receivables
----0.77
Total Trade Receivables
0.314.140.980.40.77
Other Current Assets
---11.18-
Total Current Assets
31.9969.9330.4837.244.21
Net Property, Plant & Equipment
3.683.434.074.9849.65
Other Intangible Assets
41.5444.0146.448.78108.79
Long-Term Investments
1.466.40.910.640.94
Other Long-Term Assets
0.190.190.20.180.17
Total Assets
78.86123.9682.0591.78101.88
Accounts Payable
8.827.729.38.549.61
Accrued Expenses
1.22.040.350.821.05
Short-Term Debt
9.977.26.43.091.61
Current Portion of Leases
0.770.60.860.880.76
Other Current Liabilities
3.222.671.892.943.74
Total Current Liabilities
24.920.2218.816.2716.76
Long-Term Debt
21.8335.6635.5137.2330.8
Long-Term Leases
2.812.683.033.593.97
Other Long-Term Liabilities
1.561.591.742.042.46
Total Long-Term Liabilities
26.239.9340.2842.8637.22
Total Liabilities
51.160.1559.0859.1253.99
Common Stock
4.494.394.333.713.71
Treasury Stock
-0.34-0.45-0.41-0.55-0.16
Additional Paid-in Capital
77.7177.7476.6465.6165.61
Retained Earnings
-54.11-17.87-57.59-36.11-21.26
Shareholders' Equity
27.7663.8122.9832.6647.89
Total Liabilities & Equity
78.86123.9682.0591.78101.88
Total Debt
35.3846.1345.844.7937.13
Net Cash (Debt)
-3.719.66-16.31-19.176.3
Net Cash Growth
-----67.26%
Net Cash Per Share
-0.170.90-0.83-1.030.35
Book Value
27.7663.8122.9832.6647.89
Book Value Per Share
1.252.931.171.762.64
Tangible Book Value
-13.7919.8-23.43-16.13-60.9
Tangible Book Value Per Share
-0.620.91-1.20-0.87-3.35